Description: AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson's, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
Home Page: www.acimmune.com
ACIU Technical Analysis
Building B
Lausanne,
1015
Switzerland
Phone:
41 21 345 91 21
Officers
| Name | Title |
|---|---|
| Dr. Andrea Pfeifer Ph.D. | Co-Founder, CEO & Director |
| Mr. Piergiorgio Donati | Chief Technical Operations Officer |
| Dr. Marie Kosco-Vilbois | Chief Scientific Officer |
| Mr. Jean-Fabien Monin | Chief Admin. Officer |
| Prof. Johannes Rolf Streffer M.D. | Chief Medical Officer |
| Mr. Christopher Roberts | Interim CFO & VP of Fin. |
| Mr. Joshua Drumm Ph.D. | Head of Investor Relations |
| Mr. Alexandre Caratsch | Gen. Counsel |
| Judith Moore | Global Head of Communications |
| Mr. Julian Snow | VP of U.S. Fin. & Corp. Devel. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9078 |
| Price-to-Sales TTM: | 44.1027 |
| IPO Date: | 2016-09-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |